Approved for One Thing, Used for Another: The Regulatory Gap at the Heart of Trazodone Prescribing

There is something quietly unusual about trazodone's place in American medicine. Walk into almost any primary care clinic or psychiatry practice, and you will find it prescribed regularly—often as a first-line recommendation for patients struggling to sleep. Yet the Food and Drug Administration has never formally approved trazodone for insomnia. Its label, unchanged in its fundamental scope since the early 1980s, still reads: major depressive disorder. The gap between that narrow regulatory footprint and the drug's sprawling real-world application is not an accident or an oversight. It is the product of intersecting forces in pharmacology, economics, clinical practice, and drug regulation that reveal something important about how medicine actually works in the United States.

What the FDA Label Actually Says—and What It Doesn't

Trazodone was approved by the FDA in 1981 under the brand name Desyrel, developed as an antidepressant with a mechanism distinct from the tricyclic agents that dominated the market at the time. The approval was granted specifically for major depressive disorder, and that indication has never been formally expanded. There is no FDA-approved indication for insomnia disorder, generalized anxiety disorder, post-traumatic stress disorder, or any of the other conditions for which trazodone is routinely prescribed today.

This matters for several reasons. An FDA approval represents the agency's formal determination that a drug is safe and effective for a specific use, based on a defined body of clinical evidence. When physicians prescribe outside that determination, they are operating under a different—though entirely legal—framework. Off-label prescribing is permitted in the United States, and it is practiced widely. Estimates suggest that between 10 and 20 percent of all prescriptions written in this country are for off-label uses. In psychiatry, that figure climbs considerably higher. Trazodone, in this sense, is not an outlier. It is one of the clearest illustrations of how a drug's clinical life can diverge substantially from its regulatory biography.

How a Depression Drug Became America's Sleep Aid

The story of trazodone's transformation from antidepressant to de facto sleep medication is largely a story about side effects repurposed as therapeutic tools. When trazodone was first introduced, its sedating properties were considered a liability—a tolerability concern that made it less appealing than emerging alternatives. Clinicians noticed, however, that patients taking trazodone were sleeping better. In lower doses than those required for antidepressant effect, the sedation was pronounced and clinically useful without the dependency risks associated with benzodiazepines or the more serious adverse effect profiles of older tricyclic agents.

By the time selective serotonin reuptake inhibitors began displacing trazodone as a first-choice antidepressant in the late 1980s and 1990s, many prescribers had already begun using it at low doses—typically 25 to 100 milligrams—specifically for sleep. The drug's generic availability, which arrived early and drove prices down substantially, made it an economically accessible option. Its non-controlled status meant no special prescribing requirements. These practical advantages, layered atop clinical familiarity, created the conditions for widespread off-label adoption.

Today, research consistently shows that insomnia is the primary indication driving the majority of trazodone prescriptions in the United States. A drug approved for depression is, in practice, functioning as one of the most commonly used sleep medications in the country.

Why No One Has Pursued Label Expansion

The obvious question, given decades of widespread off-label use and an accumulating evidence base, is why no pharmaceutical sponsor has sought FDA approval for trazodone as a sleep aid. The answer is almost entirely economic, and it illustrates a structural limitation in how drug development incentives function.

Pursuing a new FDA indication requires conducting the controlled clinical trials the agency mandates for approval. Those trials are expensive—often running into hundreds of millions of dollars for a comprehensive submission package. For a drug that has been generic for decades, no single manufacturer holds a patent position that would allow them to recoup that investment through exclusive market pricing. Any company that funded the approval process would be creating a regulatory benefit that all generic competitors could immediately exploit. The financial logic simply does not support the investment.

This creates a durable paradox: trazodone is used so widely for insomnia that formal approval might seem redundant, yet the very genericness that enabled its widespread adoption is the same factor that blocks the approval pathway. The FDA label, in this case, is not a reflection of where the clinical evidence points. It is a reflection of where pharmaceutical economics have stalled.

What This Means for Patients and Providers

For patients, the regulatory gap has real implications, even if the day-to-day prescribing experience feels seamless. When a drug is used off-label, the formal FDA-reviewed evidence base for that specific use may be thinner than patients assume. In trazodone's case, the evidence supporting its use for insomnia is reasonably substantial—multiple randomized controlled trials and systematic reviews have examined its sleep-related effects—but it has not been subjected to the same rigorous, standardized FDA review process that governs labeled indications.

This does not mean the prescribing is inappropriate. Evidence-based off-label use is a legitimate and often necessary part of medical practice. But it does mean that patients deserve transparency about what their prescription is and is not based on. A provider who prescribes trazodone for insomnia should ideally communicate that the drug carries no FDA approval for that purpose, while also explaining the clinical rationale and available evidence. That conversation is not always happening as consistently as it should.

For prescribers, the off-label landscape creates professional and liability considerations worth acknowledging. Physicians are generally protected when off-label prescribing reflects accepted medical practice and is supported by credible evidence. Trazodone for insomnia comfortably meets that standard in most clinical circles. But the absence of a formal label means there is no FDA-approved prescribing information specific to that use—no standardized dosing guidance, no formally reviewed contraindication list for that indication, no package insert tailored to the sleep context.

The Broader Lesson in Trazodone's Trajectory

Trazodone's regulatory situation is not unique, but it is unusually visible. The drug has been in clinical use long enough, and its off-label applications have become common enough, that the gap between its FDA label and its actual prescribing profile is difficult to ignore. In some respects, the situation reflects a system working as designed: physicians are permitted to exercise clinical judgment, evidence accumulates outside formal approval channels, and useful treatments reach patients even when the regulatory machinery has not caught up.

In other respects, it highlights a genuine gap in how the United States evaluates and communicates drug safety and efficacy. When a medication is used primarily for a purpose the FDA has never formally reviewed, patients and providers are navigating on evidence that exists but has never been officially synthesized and scrutinized in the way that formal approval demands.

Trazodone will almost certainly continue to be prescribed off-label for insomnia and anxiety for the foreseeable future. The economics of label expansion are unlikely to change. What can change is the quality of the clinical conversation surrounding that prescribing—one that acknowledges the regulatory reality while remaining grounded in the evidence that, imperfect as its formal status may be, continues to support trazodone's role in contemporary psychiatric and primary care practice.